|Bid||1.0900 x 1000|
|Ask||1.1100 x 2200|
|Day's Range||1.0800 - 1.1023|
|52 Week Range||1.0700 - 9.6780|
|Beta (3Y Monthly)||-2.64|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Even the best investor on earth makes unsuccessful investments. But serious investors should think long and hard about...
Amidst a continued effort to expand, Innovate BioPharmaceuticals has brought on a full-time chief financial officer, which it hopes will lead a campaign to raise more capital to finance its clinical trials.
Bringing its newly raised capital to bear, a Triangle-based pharmaceutical company has launched a historic trial for celiac disease.
Just months after exiting a leadership position at another Triangle public company, one career researcher has been tapped as the CSO of another.
With wind in its sails from a positive data read-out, one Triangle pharmaceutical company is bringing in $8.7 million in another offering to fund a phase 3 trial.
For the second time in less than seven days a Raleigh-based pharmaceutical company has announced millions in fundraising, extending a long line financial deals to extend its capital.
If you want to know who really controls Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as Read More...
Following Innovate Biopharmaceuticals’ reverse merger with California’s Monster Digital, the company has been busy raising funds for operations.
Innovate Biopharmaceuticals Inc’s (NASDAQ:INNT): Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. With the latest financial year loss of -US$11.6m and a trailing-twelve monthRead More...
Investors need to pay close attention to Innovate Biopharmaceuticals (INNT) stock based on the movements in the options market lately.